What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage II Melanoma
Jeffrey S. Weber, MD, PhD
PeerManesh R. Patel, MD
PeerSapna Patel, MD
PeerManaging Immunotherapy-Related Adverse Events during Adjuvant Treatment for Resectable Melanoma
Mario E. Lacouture, MD
PeerACC 2024: VOYAGER PAD Part 2
Marc P. Bonaca, MD, MPH
PeerAlcibiades J. Rodriguez, MD, FAASM
Peer